Navigation Links
Centromeres cross over, a lot
Date:6/12/2008

Recombination at centromeres is higher than anywhere else on the chromosome, even though methyltransferases do their best to prevent it, say Jaco et al., as published in the June 16 issue of the Journal of Cell Biology.

Centromeric recombination has been hard to study because the DNA at centromeres is so repetitiveit's hard to see when a segment has switched chromatids. Jaco et al. have now addressed this challenge by using CO-FISH (chromosome orientation fluorescence in situ hybridization). After replication, the two new strands are digested away, leaving the two old strands. Because the strands are complementary in sequence, they can be tagged with strand-specific fluorescent probes. Using just one probe, only one chromatid would show a signal if no recombination had occurred.

Instead, the authors found that both chromatids fluoresced. And not just at one pointon average, the authors counted, centromeres had undergone 15 recombination events. This is about six times the rate of recombination as that seen for an equal length of telomeric DNA, and 175 times the rate for genomic DNA as a whole.

Telomeric recombination is inhibited by protein complexes called shelterins and by DNA methylation. The centromere has no shelterin, but it is methylated. Knockdown of DNA methyltransferases increased recombination at the centromere by about 50%, and decreased centromere length, possibly because of misalignment between repeated segments during recombination, a common problem with repetitive DNA. How methylation limits recombination, and why centromeres didn't lengthen as well as shorten, are unknown.

Their repetitive structure makes centromeres recombinogenic by nature, and the authors suggest that epigenetic regulation may ensure the continued stability of essential binding regions for proteins that link to the centromere.


'/>"/>

Contact: Emma Hill
ehill@rockefeller.edu
212-327-8011
Rockefeller University Press
Source:Eurekalert

Page: 1

Related biology news :

1. Energy Crossroads conference April 30 and May 1 at Stanford University
2. Scientists find a fingerprint of evolution across the human genome
3. Shilatifard Lab sheds light on molecular machinery required for translation of histone crosstalk
4. Gene study supports single main migration across Bering Strait
5. A mechanism to explain biological cross-talk between 24-hour body cycle and metabolism
6. Research sheds new light on how diseases jump across species
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/2/2017)... YORK , Feb. 2, 2017  EyeLock LLC, ... released a new white paper " What You Should ... The problem of ensuring user authenticity is a growing ... the authentication of users. However, traditional authentication schemes such ... Biometric authentication offers an elegant solution ...
(Date:1/30/2017)... FRANCISCO , Jan. 30, 2017   Invitae ... the fastest growing genetic information companies, today announced that ... financial results and provide 2017 guidance on Monday, February ... conference call that day at 4:45 p.m. Eastern / ... Invitae,s management team will briefly review financial results, guidance, ...
(Date:1/24/2017)... 2017 Biopharm Reports has carried out ... of nuclear magnetic resonance spectroscopy (NMR). This involved ... current practices, developments, trends and end-user plans over ... and opportunities. These areas include growth in the ... and innovation requirements, hyphenated NMR techniques, main suppliers ...
Breaking Biology News(10 mins):
(Date:2/16/2017)... GREENWICH, Conn. , Feb. 16, ... focused on venture growth investments in biotechnology and ... Josh Richardson , M.D. to Managing Director. ... companies.  He is a board observer at InfaCare ... Longitude,s investments in Aimmune Therapeutics, Akebia Therapeutics, Cadence ...
(Date:2/16/2017)...  ArmaGen, Inc., a privately held biotechnology company ... neurological disorders, today reported preliminary evidence of cognitive ... investigational therapy for the treatment of Hurler and ... or MPS I). The initial results from an ... at the 13 th annual WORLD Symposium ...
(Date:2/16/2017)... 2017   Capricor Therapeutics, Inc. (NASDAQ: ... developing first-in-class biological therapies for cardiac and other ... to terminate its license agreement with the Mayo ... Cenderitide. "Our decision to return these ... our efforts to advance our core cell and ...
(Date:2/16/2017)... , February 16, 2017 ... the infusion of innovative telemedicine application, new and ... that are experiencing a boom worldwide. The healthcare ... advancement of technologies, services and new therapies for ... RQHTF) (TSX-V: RHT), Cellectar Biosciences, Inc. (NASDAQ: ...
Breaking Biology Technology: